Literature DB >> 499299

Absolute bioavailability of quinidine in two sustained release preparations.

J P Amlie, L Storstein, B Olsson, D Fremstad, S Jacobsen.   

Abstract

The bioavailability of quinidine in two sustained release preparations A and B has been compared in three females and three males with i.v. administration of quinidine. The initial rate of oral absorption did not differ between the two drug preparations; the peak concentration was observed after 4 h both for A and B, but was significantly higher after B. A slower decrease in plasma concentration was observed after preparation A than B. Absolute bioavailability did not differ significantly between A (median values 78.4%) and B (median 87.1%). Drug absorption in vivo was in good agreement with the results of in vitro dissolution tests on both preparations. The slower decrease in plasma concentration found for the new sustained release form of quinidine should be of clinical advantage.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499299     DOI: 10.1007/bf00644965

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  The effect of congestive heart failure on quinidine pharmacokinetics.

Authors:  W G Crouthamel
Journal:  Am Heart J       Date:  1975-09       Impact factor: 4.749

2.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

3.  Concentrations of quinidine in blood following delayed-absorption tablets.

Authors:  E M L DITLEFSEN
Journal:  Acta Med Scand       Date:  1954

Review 4.  Antiarrhythmic prophylaxis in ambulatory patients with coronary heart disease.

Authors:  J Koch-Weser
Journal:  Arch Intern Med       Date:  1972-05

5.  Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.

Authors:  D J Greenblatt; H J Pfeifer; H R Ochs; K Franke; D S MacLaughlin; T W Smith; J Koch-Weser
Journal:  J Pharmacol Exp Ther       Date:  1977-08       Impact factor: 4.030

Review 6.  Quinidine syncope and the delayed repolarization syndromes.

Authors:  E W Reynolds; C R Vander Ark
Journal:  Mod Concepts Cardiovasc Dis       Date:  1976-08

7.  Quinidine kinetics in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

8.  Correlation between plasma quinidine and cardiac effect.

Authors:  I R Edwards; B W Hancock; R Saynor
Journal:  Br J Clin Pharmacol       Date:  1974-12       Impact factor: 4.335

9.  Absolute quinidine bioavailability.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

10.  Pharmacokinetic studies of quinidine in patients with arrhythmias.

Authors:  K A Conrad; B L Molk; C A Chidsey
Journal:  Circulation       Date:  1977-01       Impact factor: 29.690

View more
  2 in total

Review 1.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.